Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy

American Journal of Nephrology

Volumn 33, Issue 3, 2011, Pages 269-276

  Ari, Elif ^a   Yilmaz, Yusuf ^a   Kedrah, Alla Elden ^a   Alahdab, Yesim ^a   Cakalagaoglu, Fulya ^a   Arikan, Hakki ^a   Kocak, Hüseyin ^b   MacUnluoglu, Beyza ^a   Atakan, Aydin ^a   Kahveci, Arzu ^a   Asicioglu, Ebru ^a   Tuglular, Serhan ^a   Ozener, Cetin ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Acute renal failure; Contrast induced nephropathy; Terlipressin

Indexed keywords

CREATININE; INDOMETACIN; MEGLUMINE DIATRIZOATE; N(G) NITROARGININE METHYL ESTER; SODIUM; TERLIPRESSIN; UNCLASSIFIED DRUG; UROVIST ANGIOGRAPHIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY TUBULE NECROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; VENOUS CONGESTION;

ACUTE KIDNEY INJURY; ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; KIDNEY FUNCTION TESTS; LYPRESSIN; RATS; RATS, INBRED BB; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 79952101944     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324764     Document Type: Article

References (31)

1. Mautone A, Brown JR: Contrast-induced ne-phropathy in patients undergoing elective and urgent procedures. J Interv Cardiol 2010; 23: 78-85.
2. Sterling KA, Tehrani T, Rudnick MR: Clini-cal significance and preventive strategies for contrast-induced nephropathy. Curr Opin Nephrol Hypertens 2008; 17:616-623.
3. Bartorelli AL, Marenzi G: Contrast-induced nephropathy. J Interv Cardiol 2008; 21:74-85. (Pubitemid 351178401)
4. Rudnick M, Feldman H: Contrast-induced nephropathy: what are the true clinical con-sequences? Clin J Am Soc Nephrol 2008; 3: 263-272.
5. Mehran R: Contrast-induced nephropathy remains a serious complication of PCI. J In-terv Cardiol 2007; 20:236-240. (Pubitemid 46808882)
6. Al-Ghonaim M, Pannu N: Prevention and treatment of contrast-induced nephropathy Tech Vasc Interv Radiol 2006; 9: 42-49. (Pubitemid 46670027)
7. Van Praet JT, De Vriese AS: Prevention of contrast-induced nephropathy: a critical re-view. Curr Opin Nephrol Hypertens 2007; 16: 336-347. (Pubitemid 46944332)
8. Schweiger MJ, Chambers CE, Davidson CJ, Blankenship J, Bhalla NP, Block PC, Dervan JP, Gasperetti C, Gerber L, Kleiman NS, Kro-ne RJ, Phillips WJ, Siegel RM, Uretsky BF, Laskey WK: Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular pro-cedures. Catheter Cardiovasc Interv 2007; 69:135-140. (Pubitemid 46052605)
9. Lameire NH: Contrast-induced nephropa-thy-prevention and risk reduction. Nephrol Dial Transplant 2006; 21:i11-i23.
10. Lebrec D: Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther 2004; 20(suppl 3):65-67. (Pubitemid 39279044)
11. Morelli A, Ertmer C, Pietropaoli P, Westphal M: Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. Expert Opin Pharmacother 2009; 10: 2569-2575.
12. Pesaturo AB, Jennings HR, Voils SA: Terli-pressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006; 40:2170-2177. (Pubitemid 44954436)
13. Singer M: Arginine vasopressin vs. terlipres-sin in the treatment of shock states. Best Pract Res Clin Anaesthesiol 2008; 22:359-368. (Pubitemid 351804051)
14. Fabrizi F, Dixit V, Messa P, Martin P: Terli-pressin for hepatorenal syndrome: a meta-analysis of randomized trials. Int J Artif Or-gans 2009; 32: 133-140.
15. Sagi SV, Mittal S, Kasturi KS, Sood GK: Ter-lipressin therapy for reversal of type 1 hepa-torenal syndrome: a meta-analysis of ran-domized controlled trials. J Gastroenterol Hepatol 2010; 25:880-885.
16. Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F: Terli-pressin improves renal function in patients with cirrhosis and ascites without hepatore-nal syndrome. Hepatology 2007; 46: 1863-1871.
17. Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Hari-moto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C: Effects of terlipressin on sys-temic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hep-atol 2009; 24:1791-1797.
18. Magan AA, Khalil AA, Ahmed MH: Terli-pressin and hepatorenal syndrome: what is important for nephrologists and hepatolo-gists. World J Gastroenterol 2010; 16: 5139-5147.
19. Ortega R, Ginès P, Uriz J, Cárdenas A, Cala-horra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J: Terlipressin therapy with and without albumin for pa-tients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepa-tology 2002; 36:941-948.
20. Kiemer AK, Fürst R, Vollmar AM: Vasopro-tective actions of the atrial natriuretic pep-tide. Curr Med Chem Cardiovasc Hematol Agents 2005; 3:11-21. (Pubitemid 40057727)
21. Tahara A, Saito M, Tsukada J, Ishii N, To-mura Y, Wada K, Kusayama T, Yatsu T, Uchi-da W, Tanaka A: Vasopressin increases vas-cular endothelial growth factor secretion from human vascular smooth muscle cells. Eur J Pharmacol 1999; 368:89-94. (Pubitemid 29106418)
22. Doi K, Noiri E, Fujita T: Role of vascular en-dothelial growth factor in kidney disease. Curr Vasc Pharmacol 2010; 8:122-128.
23. Huang YT, Lin LC, Chern JW, Lin HC, Hong CY: Portal hypotensive effects of combined terlipressin and DL-028, a synthetic alpha 1 adrenoceptor antagonist administration on anesthetized portal hypertensive rats. Liver 1999; 19: 129-134.
24. Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003; 1: CD002147.
25. Agmon Y, Peleg H, Greenfield Z: Nitric oxide and prostanoids protect the renal outer me-dulla from radiocontrast toxicity in the rat J Clin Invest 1994; 94: 1069-1075. (Pubitemid 24286448)
26. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, Uzum A, Ersoy R Sozmen EY: Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008; 23: 853-859. (Pubitemid 351767560)
27. Wang YX, Jia YF, Chen KM, Morcos SK: Radiographic contrast media induced ne-phropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001; 74:1103-1108. (Pubitemid 34071332)
28. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to- mesenchymal transition. J Clin Invest 2007; 117:3810-3820. (Pubitemid 350224091)
29. Kagan A, Sheikh-Hamad D: Contrast-in-duced kidney injury: focus on modifiable risk factors and prophylactic strategies. Clin Cardiol 2010; 33: 62-66.
30. Persson PB, Hansell P, Liss P: Pathophysiol-ogy of contrast medium-induced nephropa-thy. Kidney Int 2005; 68:14-22.
31. Moore E, Bellomo R, Nichol A: Biomarkers of acute kidney injury in anesthesia, inten-sive care and major surgery: from the bench to clinical research to clinical practice. Mi-nerva Anestesiol 2010; 76:425-440.